The DOI matches its Crossref record.
Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series
Abstract
IMPORTANCE Bullous pemphigoid is an autoimmune blistering disorder occurring mostly in the elderly that lacks adequate treatments OBJECTIVE: To describe our experience using dupilumab in a series of patients with bullous pemphigoid METHODS: This is a case series of patients from five academic centers receiving dupilumab for bullous pemphigoid Patients were eligible if they had a clinical diagnosis of BP confirmed by lesional skin biopsy evaluated by hematoxylin-eosin staining, and/or direct immunofluorescence (DIF) and/or enzyme linked immunosorbent assay (ELISA) for BP180 and/or BP230. . RESULTS We identified 13 patients. The average age of the patients was 76.8 and the average duration of bullous pemphigoid prior to dupilumab initiation was 28.8 months (range 1 to 60 months). 92.3% (12/13) of patients achieved either disease clearance or satisfactory response. Satisfactory response was defined as clinician documentation of disease improvement and patient desire to stay on the medication without documentation of disease clearance. 53.8% (7/13) of patients achieved total clearance of their bullous pemphigoid. No adverse events were reported. LIMITATIONS Include small sample size, lack of a control group, lack of a standardized assessment tool, and lack of standardized safety monitoring. CONCLUSIONS Dupilumab may be an additional treatment for BP, leading to disease clearance or satisfactory response in 92.3% of patients including in those who previously failed conventional therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Borradori, L., Van Beek, N., Feliciani, C., Tedbirt, B., Antiga, E., Bergman, R., Böckle, B. C., Caproni, M., Caux, F., Chandran, N. S., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18220 · Cited by 277
Unmet medical needs in chronic, non-communicable inflammatory skin diseases
Ujiie, H., Rosmarin, D., Schön, M. P., Ständer, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., Cole, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.875492 · Cited by 158
Metadata
- Authors
- Abdat, R., Waldman, R. A., de Bedout, V., Czernik, A., Mcleod, M., King, B., Gordon, S., Ahmed, R., Nichols, A., Rothe, M., & Rosmarin, D.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 83
- Issue
- 1
- Pages
- 46-52
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W3011657961
- Cited by
- 210
- References
- 0
- FWCI
- 17.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. https://app.cochat.ai/papers/10.1016/j.jaad.2020.01.089
- The paper
- Abdat, R., Waldman, R. A., de Bedout, V., Czernik, A., Mcleod, M., King, B., Gordon, S., Ahmed, R., Nichols, A., Rothe, M., & Rosmarin, D. (2020). Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2020.01.089
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.